Table Graph
   

hydroxychloroquine plus macrolides - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.40 [1.03, 1.90]< 10%1 study (-/1)1.6 %NAnot evaluable crucial-
death or transfer to ICU 0.45 [0.21, 0.97]< 10%1 study (-/1)98.0 %NAnot evaluable crucial-
deaths 0.84 [0.53, 1.33]< 188%10 studies (3/7)77.3 %seriouslow lowcrucial-
deaths (time to event analysis only) 0.84 [0.37, 1.92]< 193%5 studies (1/4)66.2 %seriousnot evaluable lowcrucial-
clinical deterioration 0.53 [0.17, 1.72]< 192%2 studies (1/1)85.4 %seriousnot evaluable lowimportant-
clinical improvement 0.81 [0.54, 1.22]> 10%1 study (1/-)15.5 %NAnot evaluable important-
clinical improvement (14-day) 1.01 [0.58, 1.76]> 10%1 study (1/-)51.4 %NAnot evaluable important-
hospitalization 0.38 [0.27, 0.54]< 10%1 study (-/1)100.0 %NAnot evaluable important-
mechanical ventilation 1.20 [0.69, 2.08]< 142%2 studies (1/1)26.3 %seriousnot evaluable lowimportant-
mechanical ventilation (time to event analysis only) 0.43 [0.16, 1.14]< 10%1 study (-/1)95.5 %NAnot evaluable important-
ICU admission 1.24 [0.26, 5.80]< 10%1 study (1/-)39.3 %NAnot evaluable non important-

safety endpoints 00

cardiac arrest 2.13 [1.12, 4.05]< 10%1 study (-/1)1.1 %NAnot evaluable important-
serious adverse events 1.87 [0.36, 9.75]< 10%1 study (1/-)23.0 %NAnot evaluable important-
abnormal ECG findings 1.55 [0.89, 2.68]< 10%1 study (-/1)5.9 %NAnot evaluable non important-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %NAnot evaluable non important-
adverse events 2.22 [1.43, 3.44]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
arrhythmia 2.21 [1.40, 3.49]< 10%2 studies (1/1)0.0 %seriousnot evaluable lownon important-
elevated liver enzymes 3.48 [1.40, 8.64]< 10%1 study (1/-)0.4 %NAnot evaluable non important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %NAnot evaluable non important-

AE of interest endpoints 00

Thromboembolic events 0.89 [0.31, 2.55]< 10%1 study (1/-)58.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons